China Fund News reporter Nan Shen
Recently, an article appeared on the Internet, "A 19-year-old boy died mysteriously, and his blood was drawn 16 times in a row at a plasma station." The media published relevant reports on March 18. On March 19, the local Relevant departments issued a "situation report". The plasma station involved is Xinzhou Tiantan Biological Plasma Apheresis Co., Ltd., a subsidiary of the listed company Tiantan Biological.
html At noon on March 20, Tiantan Biotechnology issued an "explanatory announcement", saying that the shortest plasma donation interval of 12 days mentioned in the report was false information. After querying the plasma donor's basic information such as age and the time of plasma donation, Relevant physical examination information and conditions meet the requirements for pulp collection. The announcement also stated that the Xinzhou Pulp Station has taken the initiative to cease operations and will actively cooperate with the investigation of relevant departments. According todata, Tiantan Biotech is one of the earliest companies in China to engage in the industrial production of blood products, and blood product revenue accounts for more than 99% of its operating income. In 2022, the company will achieve operating income of 4.261 billion yuan and net profit of 881 million yuan.
The local government issued a "situation report"
html At 21:07 pm on March 19, the Health and Sports Bureau of Xinfu District, Xinzhou City, Shanxi Province issued a situation report.
reported that on the evening of March 16, an article appeared on the Internet about "the mysterious death of a 19-year-old boy who had his blood drawn 16 times in a row at a plasma station"; on March 18, a certain media published "8 months of paid Donated plasma 16 times? A 19-year-old Shanxi boy died suddenly, and his family members questioned the report that the plasma station was "pulling people's heads." It reflected that Zhao, who lived in Jingle County, passed away and had collected plasma at the Xinzhou Tiantan Biotechnology Center in Xinfu District, Xinzhou City. Ltd. has donated plasma, which has attracted the attention of society, media and netizens.
In this regard, the Xinfu District Committee and District Government attached great importance to it, and immediately established an investigation and disposal work headed by the leaders of the District Committee and District Government, and composed of the District Health and Sports Bureau, the District Discipline Inspection and Supervision Committee, and the branch directly under the Xinzhou Municipal Public Security Bureau. Special class to investigate network reports. "Currently, the investigation has been fully launched, and we will announce the relevant information to the public in a timely manner." The
report showed that the company involved, Xinzhou Tiantan Biopheresis Plasma Co., Ltd., is a subsidiary of China National Pharmaceutical Group Co., Ltd. and was approved to be established in 2011. , carry out plasma collection business in some counties and districts in Xinzhou City.
On the afternoon of March 19, the company involved has suspended operations for rectification and is cooperating with the investigation. The Xinfu District work team has stationed at the company involved and is carefully investigating and verifying the company's plasma collection organization and mobilization, health consultation, physical examination, hemoglobin test and other work aspects, as well as the deceased Zhao's donation of plasma, and will treat the investigation as Verification results will be dealt with accordingly in accordance with the law.
Previously, according to the New Yellow River report of Jinan Daily, on January 15, 2024, Zhao Wei, a 19-year-old boy who lived in Jingle County, Xinzhou City, Shanxi Province, died suddenly at home. When his father, Zhao Zhijie, was sorting through his belongings, he discovered that Zhao Wei was suspected of having his plasma collected as many as 16 times in the eight months before his death, with the shortest interval between "blood sales" being 12 days.
Among Zhao Wei's relics was a check-up sheet issued by a local hospital ten days before his death. The diagnosis showed that he was severely anemic and suspected of having hematopoietic dysfunction.
Zhao Wei’s mobile phone chat records record the process of him being transported to the “Xinzhou Plasma Station” to sell his plasma. The “connector” paid him about 260 yuan to 300 yuan each time. Zhao Zhijie believes that the plasma station is responsible for Zhao Wei's unexpected death.
Tiantan Bio: The conditions for plasma donors meet the requirements
html At noon on March 20, Tiantan Bio issued an explanation announcement.
announced that recently, the company has paid attention to relevant media reports of its affiliated Xinzhou Tiantan Biological Apheresis Plasma Co., Ltd. (hereinafter referred to as "Xinzhou Plasma Station"). In response to relevant media reports, the company attaches great importance to and quickly verifies relevant matters. The relevant situation is now explained as follows:
1. The shortest pulp donation interval of 12 days mentioned in the report is false information. Xinzhou Pulp Station strictly follows the relevant Regulations ensure that the interval between plasma donors’ two plasma donations is no less than 14 days. At the same time, after inquiring about the plasma donor’s basic information such as age and relevant physical examination data when donating plasma, it was found that the conditions met the requirements for plasma collection.
2. The company's plasma stations operate legally in accordance with relevant requirements such as the National Health Commission's "Quality Management Standards for Plasma Apheresis Stations", "Quality Management Standards for Plasma Apheresis Stations Laboratories", and "Technical Operating Procedures for Plasma Apheresis Stations". The company's pulp stations have established a relatively complete quality management system and continue to strengthen the compliance operations of the pulp stations.
3. The company is deeply saddened and regretful for the loss of a young life. At present, the Xinzhou Pulp Station has taken the initiative to close down, and will actively cooperate with the relevant investigations of the Xinfu District Health and Sports Bureau.
4. The company will continue to adhere to the management philosophy of "practice in accordance with the law and operate in compliance with regulations", and continue to strengthen the compliance operation of plasma stations to effectively ensure the safety of plasma donors and the quality of raw plasma.
Public information shows that Tiantan Biotech was listed in 1998, and its main business is the research and development, manufacturing, sales and consulting services of blood products. After two major asset reorganizations in 2010 and 2017, Tiantan Biotechnology became a specialized blood products operating company of China National Biotechnology Co., Ltd.
Currently, Tiantan Biotech owns six blood product manufacturers including Chengdu Rongsheng, Lanzhou Blood, Shanghai Blood, Wuhan Blood, Guizhou Blood, and Xi'an Blood. Currently, the company has 102 plasma apheresis stations (including sub-stations) in 16 provinces and autonomous regions across the country, including 70 operational plasma apheresis stations (including sub-stations) and 32 plasma apheresis stations in preparation for construction. The scale of collection of plasma from healthy people is in the leading position in the country.
In 2022, the company achieved operating income of 4.261 billion yuan, a year-on-year increase of 15.92%, and achieved a net profit of 881 million yuan, a year-on-year increase of 15.92%; in the first three quarters of 2023, the company achieved revenue of 4.022 billion yuan, a year-on-year increase of 38.09%, and achieved a net profit 887 million yuan, a year-on-year increase of 47.69%.
Judging from the current stock price, Tiantan Biotech has not been affected by this emergency yet, and its latest market value is approximately 44.6 billion yuan.
Editor: Joey
Copyright Statement
"China Fund News" owns the copyright to the original content published on this platform. Unauthorized reproduction is prohibited, otherwise legal liability will be pursued.
